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Introduction {#sec001}
============

Human cytomegalovirus (HCMV) is a widespread opportunistic ß-herpesvirus that has latently infected approximately 60--100% of the world's population \[[@pone.0169420.ref001]\]. It is also the most common cause of congenital viral infection in the developed world, occurring in 0.5--2.0% of pregnancies \[[@pone.0169420.ref002], [@pone.0169420.ref003]\]. HCMV infection is usually asymptomatic, although the virus remains latent throughout life and may reactivate at any time. Among immunosuppressed patients and newborns with congenital infections, the virus provokes a number of disparate outcomes. A number of factors can affect the interaction between the host immune system and the virus, and the major determinants of HCMV disease appear to be host factors.

Host-viral interactions are initiated *via* host recognition of pathogen-associated molecular patterns (PAMPs) of the virus. This recognition occurs through host pattern recognition receptors (PRRs), including Toll-like receptors (TLRs), RIG-I-like receptors (RLRs), NOD-like receptors (NLRs), and C-type lectin receptors (CLRs). Human TLRs are present on the cell membrane (TLR1, -2, -4, -5, -6) and within endosomal compartments (TLR3, -7, -8, and -9), while NLRs and RIG-I helicases are intracellular sensors. Viral RNA is recognized by endosomal TLRs, such as TLR3, -7, and -8, as well as by TLR-independent pathways, and can activate the cytoplasmic RNA helicases RIG-I and MDA5 \[[@pone.0169420.ref004]--[@pone.0169420.ref007]\]. TLR3 recognizes poly(I:C), a synthetic double-stranded RNA (dsRNA) analog, as well as viral dsRNA that can be generated as an intermediate during the replication cycle of single-stranded RNA (ssRNA) or DNA viruses \[[@pone.0169420.ref008]--[@pone.0169420.ref010]\]. Interactions of intracellular TLR3 with murine CMV (MCMV) are related to the binding of the dsRNA molecules produced during virus replication \[[@pone.0169420.ref011]\]. TLR7 and TLR8 detect viral and non-viral ssRNA \[[@pone.0169420.ref012], [@pone.0169420.ref013]\], while TLR9 recognizes unmethylated cytosine-phosphate-guanosine (CpG) motifs from DNA viruses, including MCMV and herpes simplex virus (HSV-1/HSV-2) \[[@pone.0169420.ref014], [@pone.0169420.ref015]\].

Few studies have suggested a role of *TLR* polymorphisms in the HCMV-associated disease pathology. Associations between *TLR2* \[[@pone.0169420.ref016], [@pone.0169420.ref017]\], *TLR4* \[[@pone.0169420.ref018]\], and *TLR9* polymorphisms \[[@pone.0169420.ref019]--[@pone.0169420.ref022]\] with HCMV infection have been found. It was previously demonstrated that the *TLR9*--1486 and 2848 polymorphisms as well as the *TLR2* 1350 SNP are associated with an enhanced risk of HCMV infection and disease in newborns and infants \[[@pone.0169420.ref023]--[@pone.0169420.ref025]\]. However, little is known about the role of *TLR3* and *TLR7* polymorphisms in the pathogenesis of cytomegaly. *In vitro* experiments revealed that fibroblasts isolated from carriers of the L412F variant of *TLR3* showed reduced IFNγ and TNFα secretion in response to HCMV stimulation \[[@pone.0169420.ref026]\]. *TLR7* polymorphisms have been suggested to play a role in the development of glycoprotein B (gB) antibodies following HCMV immunization. Women that were homozygous carriers of four *TLR7* SNPs (rs179008, rs179009, rs179013 and rs179018) demonstrated a higher vaccination-induced antibody response to HCMV gB than did heterozygotes or homozygotes for the common allele \[[@pone.0169420.ref027]\].

The objective of the current study is to determine the frequencies of SNPs in the *TLR3* (rs3775290, rs3775291, rs3775296) and *TLR7* (rs179008, and rs5741880) genes and investigate the associations between these polymorphisms and HCMV infection in children. The majority of the children in this study were also involved in earlier studies on the relationship between polymorphisms in the *TLR2*, *TLR4*, and *TLR9* genes and HCMV infection \[[@pone.0169420.ref024], [@pone.0169420.ref028]\]. In an attempt to provide more definitive conclusion, all previously tested *TLR* SNPs: *TLR2* (rs121917864 and rs5743708), *TLR4* (rs4986790), and *TLR9* (rs5743836, rs187084, rs352139, and rs352140) were included in multiple testing analysis.

Materials and Methods {#sec002}
=====================

Patients {#sec003}
--------

From February 2008 to January 2011, 59 children with HCMV infection (median age 4 months; range 1--24 months) were selected for the study at the 3rd Department of Pediatrics of the Polish Mother's Memorial Hospital Research Institute in Lodz, Poland. Fifty-nine children with HCMV infection and some uninfected infants were earlier examined for the presence of *TLR2*, *TLR4*, and *TLR9* SNPs as described in our previous studies \[[@pone.0169420.ref024], [@pone.0169420.ref028]\]. Among uninfected infants, 30 out of 78 cases were analyzed for the presence of *TLR2* and *TLR4* SNPs \[[@pone.0169420.ref028]\], while 42 out of 78 were genotyped for *TLR9* SNPs. HCMV infection was confirmed by the presence of HCMV-specific antibodies and/or HCMV DNA detection in whole blood and/or urine samples. As previously described \[[@pone.0169420.ref024]\], serum samples were assessed for anti-HCMV IgG and IgM antibodies. The whole blood and urine samples were collected during the exacerbation of cytomegaly symptoms, including anemia, thrombocytopenia, pneumonia, hepatitis, hepatic dysfunction, and others. Due to selection bias, all children with HCMV infection in this study were symptomatic. Because the samples for virus detection were collected after 3 weeks of life, all children were classified as having postnatal or unproven congenital HCMV infection. The demographic and clinical characteristics of patients with HCMV infection were summarized in [Table 1](#pone.0169420.t001){ref-type="table"}. HCMV-positive children were compared with 78 unrelated seronegative and aviremic newborn infants. All subjects were of European descent, and there were no ethnic differences between the cases and the uninfected group.

10.1371/journal.pone.0169420.t001

###### Demographic and clinical characteristics of study subjects with HCMV infection.

![](pone.0169420.t001){#pone.0169420.t001g}

  Characteristics                                                  
  ---------------------------------------------------------------- -----------
  **Total No.**                                                    59
  **Mean ± SD age, months**                                        5.7 ± 5.3
  **Median (range), months**                                       4 (1--24)
  **Gender number; n (%)**[^a^](#t001fn001){ref-type="table-fn"}   
  Female                                                           20 (33.9)
  Male                                                             39 (66.1)
  **Symptoms; n (%)**[^a^](#t001fn001){ref-type="table-fn"}        
  Hematological disorders                                          25 (42.4)
  Pneumonia                                                        16 (27.1)
  Liver damage or hepatitis                                        15 (25.4)
  Neurological dysfunction                                         15 (25.4)
  CNS damage                                                       14 (23.7)
  Psychomotor retardation                                          12 (20.3)
  Jaundice                                                         11 (18.6)
  Hearing loss                                                     6 (10.2)
  IUGR                                                             5 (8.5)
  Hepatosplenomegaly                                               5 (8.5)
  Heart disease                                                    2 (3.4)
  **Anti-HCMV serologic status**                                   
  IgG-positive, IgM-negative                                       25 (42.4)
  IgG-positive, IgM-positive                                       32 (54.2)
  IgG-negative, IgM-negative                                       2 (3.4)

^a^Values are the number of infants (%).

The study protocols were approved by the Bioethics Committee of the Medical University of Lodz (RNN/120/09/KE) and the Ethics Committee of the Polish Mother's Memorial Hospital Research Institute. Parents or guardians provided written informed consent on behalf of the children to participate in this study.

*TLR* SNP analysis {#sec004}
------------------

Genomic DNA was extracted from EDTA-anticoagulated peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. The concentration and purity of DNA were measured using a NanoDrop 2000c UV-vis Spectrophotometer (Thermo Scientific, Wilmington, DE, USA). A total of 5 SNPs in the *TLR3* (rs3775290, rs3775291, and rs3775296) and *TLR7* (rs179008, rs5741880) genes were analyzed ([Table 2](#pone.0169420.t002){ref-type="table"}). The selection of SNPs was based on their possible functional effect and due to the existence of previous associations with infectious diseases. The identification of SNPs was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) using primers described previously by Noguchi et al. \[[@pone.0169420.ref029]\] (*TLR3* SNPs), Cheng et al. \[[@pone.0169420.ref030]\] (*TLR7* SNP rs179008), and Arslan et al. \[[@pone.0169420.ref031]\] (*TLR7* SNP rs5741880). Each PCR reaction contained 200 ng of genomic DNA, primers (1 μM each), dNTPs (2.5 mM), 10x *Taq* buffer (100 mM Tris-HCl, 500 mM KCl, 0.8% Nonidet-P40; pH 8.8), 2 mM MgCl~2~, and 1 U of *Taq* DNA Polymerase (Fermentas, Glen Burnie, MD, USA). The thermal cycling conditions for *TLR3* were 5 min at 95°C and 35 cycles each of 45 s at 95°C, 15 s at 56°C, and 30 s at 72°C. The PCR parameters for *TLR7* were as follows: 5 min at 94°C and 35 cycles each of 30 s at 94°C, 30 s at 52°C, and 1 min. at 72°C. The final extension was at 72°C for 7 min. The reactions were performed in the Veriti thermal cycler (Applied Biosystems, Foster City, CA, USA). The PCR-amplified fragments corresponding to the *TLR3* rs3775290 (c.1377C\>T, F459F), rs3775291 (c.1234C\>T, L412F), rs3775296 (c.-7C\>A) and *TLR7* rs179008 (c.32A\>T, Q11L), and rs5741880 (c.3+1716G\>T) polymorphisms were digested with the restriction enzymes *Taq*I, *HpyF3*I, *Mbo*II, *Xap*I, and *Hpy*188I, respectively (Fermentas, Hanover, MD, USA). The digested fragments were separated using the QIAxcel DNA Screening Kit (Qiagen) on the QIAxcel capillary electrophoresis system (Qiagen). The retention time of the PCR fragments relative to the QX Alignment Marker 15 bp/1 kb fragments was calculated using the BioCalculator software (Qiagen). The PCR-RFLP product sizes were determined by comparing the retention time with the QX DNA Size Marker 50--800 bp. The *TLR3* and *TLR7* SNPs were identified by different fragment lengths described in [Table 3](#pone.0169420.t003){ref-type="table"} and presented in [Fig 1](#pone.0169420.g001){ref-type="fig"}. For two SNPs, rs3775290 (allele C) and rs3775296 (allele A), the presence of three instead of two products was observed in some samples, possibly due to degraded DNA. We randomly selected 20% of the samples to validate the results of genotyping by PCR-RFLP assay. The obtained results were validated by direct sequencing of selected PCR products using the MiSeq system (Illumina, San Diego, CA, USA). *TLR2*, *TLR4*, and *TLR9* genotyping was done using PCR-RFLP method. Details of primers, PCR conditions, and restriction enzymes have been described elsewhere \[[@pone.0169420.ref024], [@pone.0169420.ref028]\]. Digested PCR products were analyzed using the QIAxcel capillary electrophoresis system (Qiagen).

10.1371/journal.pone.0169420.t002

###### Selected single-nucleotide polymorphisms in the *TLR3* and *TLR7* genes.

![](pone.0169420.t002){#pone.0169420.t002g}

  Gene         SNP ID      Alleles   Amino acid change   Function   MAF             
  ------------ ----------- --------- ------------------- ---------- ------- ------- -------
  ***TLR3***   rs3775290   C/T       F459F               Silent     0.321   0.273   0.272
  rs3775291    C/T         L412F     Missense            0.256      0.324   0.232   
  rs3775296    C/A                   UTR-5               0.173      0.174   0.182   
  ***TLR7***   rs179008    A/T       Q11L                Missense   0.301   0.176   0.118
  rs5741880    G/T                   Intronic            0.308      0.092   0.207   

MAF, Minor allele frequency in the Polish population (present study), European and Global population (NCBI, 1000 Genomes Project)

10.1371/journal.pone.0169420.t003

###### Restriction enzymes and length of the restriction fragments.

![](pone.0169420.t003){#pone.0169420.t003g}

  Gene         SNP                 Restriction enzyme   Genotype   Length of the restriction fragments (bp)
  ------------ ------------------- -------------------- ---------- ------------------------------------------
  ***TLR3***   rs3775290           *Taq*I               CC         39, 45, 299
  CT           39, 45, 299, 383                                    
  TT           383                                                 
  rs3775291    *HpyF3I*            CC                   31,169     
  CT           31, 169, 200                                        
  TT           200                                                 
  rs3775296    *Mbo*II             CC                   285        
  CA           37, 52, 196, 285                                    
  AA           37, 52, 196                                         
  ***TLR7***   rs179008            *XapI*               AA         64, 116, 174
  AT           64, 116, 174, 247                                   
  TT           174, 247                                            
  rs5741880    *Hpy*188I           GG                   186        
  GT           43, 143, 186                                        
  TT           43, 143                                             

bp, base pairs

![Visualization of PCR-RFLP products for *TLR3* SNP (A) and *TLR7* SNP (B) genotyping.\
Gel image: A) rs3775290: 1. wild type CC, 2. heterozygous CT, 3. homozygous recessive TT; rs3775291: 4. wild type CC, 5. heterozygous CT, 6. homozygous recessive TT; rs3775296: 7. wild type CC, 8. heterozygous CA, 9. homozygous recessive AA. B) rs179008: 1. wild type AA, 2. heterozygous AT, 3. homozygous recessive TT; rs5741880: 4. wild type GG, 5. heterozygous GT, 6. homozygous recessive TT. Alignment markers (15 bp, 1 kbp).](pone.0169420.g001){#pone.0169420.g001}

Quantification of HCMV DNA {#sec005}
--------------------------

The HCMV DNA copy number in DNA isolates from whole blood and urine samples were determined using a real-time PCR assay targeting the *UL55* gene using a 7900HT Fast Real-Time PCR System (Applied Biosystems), as described elsewhere \[[@pone.0169420.ref024], [@pone.0169420.ref032]\]. The lower limit of detection of this assay was 100 HCMV DNA copies/mL.

Statistical analysis {#sec006}
--------------------

*TLRs* genotype and allele frequencies were calculated by direct counting. All the statistical analyses, including the Hardy-Weinberg equilibrium (HWE) test and the associations of genotypes and haplotypes with HCMV infection status, were performed using the SNPSTATS program (<http://bioinfo.iconcologia.net/index.php?module=Snpstats>) \[[@pone.0169420.ref033]\]. Odds ratio (OR) and 95% confidence intervals (95% CIs) with both unadjusted and adjusted multivariate models were calculated to examine the association between the *TLR* SNPs and HCMV infection. To adjust for possible confounders, the linear model was extended to include the effects of viral load, which is a key risk factor for the development of HCMV disease. Linkage disequilibrium (LD) was analyzed by Haploview software (version 4.2; Broad Institute, Cambridge, MA, USA; <http://www.broad.mit.edu/mpg/haploview>) \[[@pone.0169420.ref034]\]. The significance of differences in the estimated allele frequencies between HCMV-infected and uninfected patient groups were examined on Haploview 4.2 using χ2 tests, and alleles were corrected using permutation test after running 1000 times. The association between the *TLR* genotype and the symptoms based on logistic regression were performed using the SPSS statistical software package for Windows 17.0 (SPSS, Chicago, IL, USA). The distribution of alleles and genotypes among the study groups was examined using the Fisher's exact test. The one-way analysis of variance (ANOVA) and Mann-Whitney U tests were used to study the association between *TLR* polymorphisms and viral load. For all statistical tests a *P*-value of ≤ 0.05 was considered to be statistically significant. Bonferroni's correction (*P*^*c*^) of the significance level was applied to account for multiple testing. The *P*^*c*^-values were count by dividing the *P*-value by the number of comparisons.

Results {#sec007}
=======

Study population {#sec008}
----------------

Viral DNA was detected and quantified in 49 of the 59 examined children with HCMV infection (83%) by real-time PCR. Among them, HCMV DNA was detected in 37/49 whole blood (75.5%) and 42/49 urine (85.7%) samples. In the remaining 10 cases, active HCMV infection was confirmed by the detection of HCMV-specific IgM antibodies. Cytomegalovirus serology assays were performed for all 59 HCMV-infected children and 78 control newborn infants. Sera from 32 infected children were positive for IgG and IgM, 25 were positive for IgG only, and 2 were IgG- and IgM-negative (see [Table 1](#pone.0169420.t001){ref-type="table"}). The anti-HCMV IgG and IgM serology results were negative for all control infants.

Frequency of *TLR3* and *TLR7* gene polymorphisms in children {#sec009}
-------------------------------------------------------------

To analyze the impact of *TLR3* and *TLR7* SNPs on the incidence of HCMV infection, a group of uninfected and HCMV-infected children was analyzed with different genetic models. To explore the data, we performed the analysis of genotype and allele frequencies of *TLR* polymorphisms, including *TLR2*, *TLR4*, and *TLR9* SNPs in the patient groups examined (see Tables [4](#pone.0169420.t004){ref-type="table"} and [5](#pone.0169420.t005){ref-type="table"}). Fifty-nine cases of HCMV infection and part of uninfected subjects has been described previously in detail for *TLR2*, *TLR4* \[[@pone.0169420.ref028]\], and *TLR9* SNPs \[[@pone.0169420.ref024]\]. The genotype and allele frequencies for all studied *TLR2*, *TLR3*, *TLR7*, and *TLR9* SNPs were in HWE in the uninfected group, while *TLR4* SNP was not (*P* ≤ 0.050) and was excluded from further analysis. With the exception of the rs3775291 SNP in the *TLR3* gene and the rs5743708 SNP in the *TLR9* gene, all polymorphisms were also in HWE in HCMV cases.

10.1371/journal.pone.0169420.t004

###### Frequency and distribution of *TLR* genotypes and their association with HCMV infection.

![](pone.0169420.t004){#pone.0169420.t004g}

  Gene           SNP           Model        Genotype              Genotype frequencies; n (%)[^a^](#t004fn001){ref-type="table-fn"}   Unadjusted     Adjusted[^b^](#t004fn002){ref-type="table-fn"}                               
  -------------- ------------- ------------ --------------------- ------------------------------------------------------------------- -------------- ------------------------------------------------ -------------- ------------ -------
  ***TLR2***     rs121917864   Codominant   CC                    59 (100%)                                                           77 (98.7%)     1.00                                             0.29           1.00         0.48
  CT             0 (0%)        1 (1.3%)     0.00 (0.00-NA)        0.00 (0.00-NA)                                                                                                                                                  
  rs5743708      Codominant    GG           57 (96.6%)            78 (100%)                                                           1.00           0.065                                            1.00           NA           
  GA             2 (3.4%)      0 (0%)       NA (0.00-NA)          NA (0.00-NA)                                                                                                                                                    
  ***TLR3***     rs3775290     Codominant   CC                    24 (40.7)                                                           38 (48.7)      1.00                                             0.33           1.00         0.042
  CT             30 (50.9)     30 (38.5)    1.58 (0.77--3.25)     3.17 (1.10--9.15)                                                                                                                                               
  TT             5 (8.5)       10 (12.8)    0.79 (0.24--2.60)     0.63 (0.07--5.88)                                                                                                                                               
  Dominant       CC            24 (40.7)    38 (48.7)             1.00                                                                0.35           1.00                                             0.068                       
  CT-TT          35 (59.3)     40 (51.3)    1\. 39 (0.70--2.74)   2.53 (0.90--7.15)                                                                                                                                               
  Recessive      CC-CT         54 (91.5)    68 (87.2)             1.00                                                                0.41           1.00                                             0.23                        
  TT             5 (8.5)       10 (12.8)    0.63 (0.20--1.95)     0.32 (0.04--2.68)                                                                                                                                               
  Overdominant   CC-TT         29 (49.1)    48 (61.5)             1.00                                                                0.15           1.00                                             0.013                       
  CT             30 (50.9)     30 (38.5)    1.66 (0.83--3.28)     3.43 (1.25--9.38)                                                                                                                                               
  rs3775291      Codominant    CC           5 (8.5)               46 (59.0)                                                           1.00           **\<0.0001**                                     1.00           **0.0001**   
  CT             49 (83.0)     24 (30.8)    18.78 (6.61--53.36)   11.50 (3.08--42.97)                                                                                                                                             
  TT             5 (8.5)       8 (10.2)     5.75 (1.35--24.49)    1.92 (0.18--20.80)                                                                                                                                              
  Dominant       CC            5 (8.5)      46 (59.0)             1.00                                                                **\<0.0001**   1.00                                             **0.0001**                  
  CT-TT          54 (91.5)     32 (41.0)    15.52 (5.59--43.11)   9.10 (2.48--33.36)                                                                                                                                              
  Recessive      CC-CT         54 (91.5)    70 (89.7)             1.00                                                                0.72           1.00                                             0.38                        
  TT             5 (8.5)       8 (10.3)     0.81 (0.25--2.62)     0.42 (0.05--3.52)                                                                                                                                               
  Overdominant   CC-TT         10 (16.9)    54 (69.2)             1.00                                                                **\<0.0001**   1.00                                             **\<0.0001**                
  CT             49 (83.1)     24 (30.8)    11.02 (4.79--25.36)   10.13 (3.09--33.13)                                                                                                                                             
  rs3775296      Codominant    CC           32 (54.2)             55 (70.5)                                                           1.00           0.12                                             64             0.55         
  CA             24 (40.7)     19 (24.4)    2.17 (1.03--4.56)     1.78 (0.64--4.96)                                                                                                                                               
  AA             3 (5.1)       4 (5.1)      1.29 (0.27--6.13)     1.06 (0.11--10.27)                                                                                                                                              
  Dominant       CC            32 (54.2)    55 (70.5)             1.00                                                                0.05           1.00                                             0.32                        
  CA-AA          27 (45.8)     23 (29.5)    2.02 (1.00--4.09)     1.66 (0.62--4.41)                                                                                                                                               
  Recessive      CC-CA         56 (94.9)    74 (94.9)             1.00                                                                0.99           1.00                                             0.91                        
  AA             3 (5.1)       4 (5.1)      0.99 (0.21--4.61)     0.88 (0.09--8.31)                                                                                                                                               
  Overdominant   CC-AA         35 (59.3)    59 (75.6)             1.00                                                                0.042          1.00                                             0.27                        
  CA             24 (40.7)     19 (24.4)    2.13 (1.02--4.43)     1.77 (0.65--4.88)                                                                                                                                               
  ***TLR7***     rs179008      Codominant   AA                    35 (59.3)                                                           39 (50.0)      1.00                                             0.51           1.00         0.5
  AT             18 (30.5)     31 (39.7)    0.65 (0.31--1.35)     0.54 (0.19--1.57)                                                                                                                                               
  TT             6 (10.2)      8 (10.3)     0.84 (0.26--2.65)     0.70 (0.13--3.68)                                                                                                                                               
  Dominant       AA            35 (59.3)    39 (50.0)             1.00                                                                0.28           1.00                                             0.25                        
  AT-TT          24 (40.7)     39 (50.0)    0.69 (0.35--1.36)     0.57 (0.22--1.52)                                                                                                                                               
  Recessive      AA-AT         53 (89.8)    70 (89.7)             1.00                                                                0.99           1.00                                             0.87                        
  TT             6 (10.2)      8 (10.3)     0.99 (0.32--3.03)     0.87 (0.17--4.45)                                                                                                                                               
  Overdominant   AA-TT         41 (69.5)    47 (60.3)             1.00                                                                0.26           1.00                                             0.28                        
  AT             18 (30.5)     31 (39.7)    0.67 (0.33--1.36)     0.57 (0.20--1.61)                                                                                                                                               
  rs5741880      Codominant    GG           24 (40.7)             37 (47.4)                                                           1.00           0.57                                             1.00           0.17         
  GT             31 (52.5)     34 (43.6)    1.41 (0.69--2.85)     0.36 (0.12--1.11)                                                                                                                                               
  TT             4 (6.8)       7 (9.0)      0.88 (0.23--3.34)     0.70 (0.13--3.79)                                                                                                                                               
  Dominant       GG            24 (40.7)    37 (47.4)             1.00                                                                0.43           1.00                                             0.082                       
  GT-TT          35 (59.3)     41 (52.6)    1.32 (0.66--2.61)     0.42 (0.15--1.15)                                                                                                                                               
  Recessive      GG-GT         55 (93.2)    71 (91.0)             1.00                                                                0.64           1.00                                             0.99                        
  TT             4 (6.8)       7 (9.0)      0.74 (0.21--2.65)     1.01 (0.20--5.27)                                                                                                                                               
  Overdominant   GG-TT         28 (47.5)    44 (56.4)             1.00                                                                0.3            1.00                                             0.068                       
  GT             31 (52.5)     34 (43.6)    1.43 (0.73--2.83)     0.38 (0.13--1.14)                                                                                                                                               
  ***TLR9***     rs5743836     Codominant   TT                    58 (98.3%)                                                          78 (100%)      1.00                                             0.19           1.00         0.08
  CC             1 (1.7%)      0 (0%)       NA (0.00-NA)          NA (0.00-NA)                                                                                                                                                    
  rs187084       Codominant    TT           17 (28.8%)            31 (39.7%)                                                          1.00           0.085                                            1.00           0.096        
  TC             36 (61%)      33 (42.3%)   1.99 (0.93--4.24)     2.82 (0.92--8.68)                                                                                                                                               
  CC             6 (10.2%)     14 (17.9%)   0.78 (0.25--2.41)     0.89 (0.15--5.13)                                                                                                                                               
  Dominant       TT            17 (28.8%)   31 (39.7%)            1.00                                                                0.18           1.00                                             0.13                        
  TC-CC          42 (71.2%)    47 (60.3%)   1.63 (0.79--3.36)     2.24 (0.75--6.71)                                                                                                                                               
  Recessive      TT-TC         53 (89.8%)   64 (82%)              1.00                                                                0.19           1.00                                             0.29                        
  CC             6 (10.2%)     14 (17.9%)   0.52 (0.19--1.44)     0.46 (0.10--2.19)                                                                                                                                               
  Overdominant   TT-CC         23 (39%)     45 (57.7%)            1.00                                                                0.03           1.00                                             0.031                       
  TC             36 (61%)      33 (42.3%)   2.13 (1.07--4.25)     2.92 (1.07--7.97)                                                                                                                                               
  rs352139       Codominant    AA           33 (55.9%)            25 (32%)                                                            1.00           **0.0011**                                       1.00           0.035        
  GA             23 (39%)      34 (43.6%)   0.51 (0.24--1.08)     0.55 (0.20--1.51)                                                                                                                                               
  GG             3 (5.1%)      19 (24.4%)   0.12 (0.03--0.45)     0.11 (0.01--0.92)                                                                                                                                               
  Dominant       AA            33 (55.9%)   25 (32%)              1.00                                                                0.005          1.00                                             0.057                       
  GA-GG          26 (44.1%)    53 (68%)     0.37 (0.18--0.75)     0.39 (0.15--1.03)                                                                                                                                               
  Recessive      AA-GA         56 (94.9%)   59 (75.6%)            1.00                                                                **0.0013**     1.00                                             0.021                       
  GG             3 (5.1%)      19 (24.4%)   0.17 (0.05--0.59)     0.15 (0.02--1.17)                                                                                                                                               
  Overdominant   AA-GG         36 (61%)     44 (56.4%)            1.00                                                                0.59           1.00                                             0.82                        
  GA             23 (39%)      34 (43.6%)   0.83 (0.42--1.65)     0.90 (0.34--2.34)                                                                                                                                               
  rs352140       Codominant    CC           17 (28.8%)            44 (56.4%)                                                          1.00           0.0051                                           1.00           0.017        
  CT             32 (54.2%)    26 (33.3%)   3.19 (1.49--6.83)     4.40 (1.41--13.75)                                                                                                                                              
  TT             10 (16.9%)    8 (10.3%)    3.24 (1.09--9.58)     4.40 (0.97--20.02)                                                                                                                                              
  Dominant       CC            17 (28.8%)   44 (56.4%)            1.00                                                                **0.0011**     1.00                                             **0.0043**                  
  CT-TT          42 (71.2%)    34 (43.6%)   3.20 (1.56--6.57)     4.40 (1.47--13.13)                                                                                                                                              
  Recessive      CC-CT         49 (83%)     70 (89.7%)            1.00                                                                0.25           1.00                                             0.33                        
  TT             10 (16.9%)    8 (10.3%)    1.79 (0.66--4.85)     1.94 (0.53--7.19)                                                                                                                                               
  Overdominant   CC-TT         27 (45.8%)   52 (66.7%)            1.00                                                                0.014          1.00                                             0.03                        
  CT             32 (54.2%)    26 (33.3%)   2.37 (1.18--4.75)     2.89 (1.09--7.63)                                                                                                                                               

^a^Values are the number of examined infants (%);

^b^Adjusted analysis was carried out for HCMV DNA copy number in whole-blood samples;

OR: odds ratio; 95% CI: 95% confidence interval; *P*, logistic regression model; NA: not available; *P*^c^, The significance level after Bonferroni's correction for multiple testing is 0.0045 (raw *P*-value/11).

10.1371/journal.pone.0169420.t005

###### The distribution of allele frequencies of TLR SNPs in infants with and without HCMV infection.

![](pone.0169420.t005){#pone.0169420.t005g}

  Gene         SNP           Allele       Allele frequencies; n (%)[^a^](#t005fn001){ref-type="table-fn"}   *P*            *P*^*b*^     
  ------------ ------------- ------------ ----------------------------------------------------------------- -------------- ------------ --------
  ***TLR2***   rs121917864   C            118 (100)                                                         155 (99.4)     0.3836       1.0000
  T            0 (0)         1 (0.6)                                                                                                    
  rs5743708    G             116 (98.3)   156 (100)                                                         0.1027         0.8160       
  A            2 (1.7)       0 (0)                                                                                                      
  ***TLR3***   rs3775290     C            78 (66.1)                                                         106 (67.9)     0.7472       1.0000
  T            40 (33.9)     50 (32.1)                                                                                                  
  rs3775291    C             59 (50.0)    116 (74.4)                                                        **\<0.0001**   **0.0010**   
  T            59 (50.0)     40 (25.6)                                                                                                  
  rs3775296    C             88 (74.6)    129 (82.7)                                                        0.1012         0.6140       
  A            30 (25.4)     27 (17.3)                                                                                                  
  ***TLR7***   rs179008      A            88 (74.6)                                                         109 (69.9)     0.391        1.0000
  T            30 (25.4)     47 (30.1)                                                                                                  
  rs5741880    G             79 (67.0)    108 (69.2)                                                        0.6879         1.0000       
  T            39 (33.0)     48 (30.8)                                                                                                  
  ***TLR9***   rs5743836     T            116 (98.3)                                                        156 (100)      0.1027       0.8160
  C            2 (1.7)       0 (0)                                                                                                      
  rs187084     T             70 (59.3)    95 (60.9)                                                         0.7919         1.0000       
  C            48 (40.7)     61 (39.1)                                                                                                  
  rs352139     G             29 (24.6)    72 (46.2)                                                         **0.0002**     **0.0030**   
  A            89 (75.4)     84 (53.8)                                                                                                  
  rs352140     C             66 (55.9)    114 (73.1)                                                        **0.0031**     **0.0300**   
  T            52 (44.1)     42 (26.9)                                                                                                  

^a^Values are the number of alleles (%); *P*, *P*-value was calculated from chi-square test; *P*^*b*^, *P*-value for estimated alleles were generated from 1000 permutations using the expectation-maximization (EM) algorithm.

The distribution of the rs3775291 and rs3775296 genotypes of the *TLR3* gene was different between HCMV-infected and uninfected individuals (see [Table 4](#pone.0169420.t004){ref-type="table"}; *P* \< 0.001 and *P* = 0.073, respectively; Fisher's exact test). The frequency of the wild-type genotype of the *TLR3* SNP rs3775291 was significantly higher in uninfected than in HCMV-infected cases (59.0% vs. 8.5%; *P* \< 0.0001; Fisher's exact test). It should be noted that the heterozygous variant of this SNP was detected more frequently among children with HCMV infection than in uninfected infants (83.0% vs. 30.8%; *P*\< 0.0001; Fisher's exact test). Consequently, the wild-type rs3775291 C allele was detected more frequently in uninfected children (74.4%) compared with HCMV-infected cases (50.0%; *P* \< 0.001; see [Table 5](#pone.0169420.t005){ref-type="table"}). No difference was observed in the distribution of the *TLR3* SNP rs3775290 or in both *TLR7* SNPs between infected and uninfected children (*P* \> 0.05). In the current study, analysis of the allele frequencies of *TLR9* SNPs showed that A (rs352139) and T (rs352140) alleles were detected more frequently in children with HCMV infection than in uninfected individuals (permutation values *P* = 0.003 and *P* = 0.03, respectively; [Table 5](#pone.0169420.t005){ref-type="table"}). No differences in the frequency of *TLR2* and *TLR4* alleles were observed.

*TLR3* L412F polymorphism is associated with the risk of HCMV infection {#sec010}
-----------------------------------------------------------------------

Single-SNP analysis revealed that a mutation present in at least one allele of the *TLR3* SNP rs3775291 was significantly associated with the risk of HCMV infection (see [Table 4](#pone.0169420.t004){ref-type="table"}). Heterozygous CT and homozygous recessive TT genotypes at the 1234 locus were associated with a significantly increased risk of infection in almost all genetic models (OR 18.78, 95% CI 6.61--53.36 in the codominant model and OR 15.52, 95% CI 5.59--43.11 in the dominant model; *P* \< 0.001). Moreover, the results suggested that the heterozygous CT genotype was mainly responsible for the observed association of this SNP with HCMV cases (OR 11.02, 95% CI 4.79--25.36; *P* \< 0.001 in the overdominant model). These associations persisted even after adjustment for multiple comparisons using Bonferroni's correction (*P*^*c*^ \< 0.001). In addition, the heterozygous genotype of the rs3775296 SNP was associated with a 2-fold increased risk of HCMV infection (OR 2.13, 95% CI 1.02--4.43; *P* = 0.042 in the overdominant model). However, this association did not reach statistical significance after Bonferroni's correction for multiple testing. No association between *TLR3* rs3775290 or any *TLR7* SNP genotypes and the risk of HCMV infection was found. In the examined children, an association of the *TLR9* SNPs rs352139 and rs352140 with HCMV infection has been confirmed ([Table 5](#pone.0169420.t005){ref-type="table"}).

There was no significant association between the *TLR3* and *TLR7* SNPs and the presence of specific HCMV symptoms, excluding hepatitis. Analysis of genetic polymorphisms of the *TLRs* in the HCMV-infected children showed that hepatitis seemed to be correlated with the presence of some genotypes, although this symptom was observed in only a small number of examined children (5 cases). The TT genotype of *TLR3* rs3775290 was detected in 2/5 children with hepatitis and was associated with a 11-fold increased risk of hepatitis in the unadjusted and adjusted models (OR 11.3, 95% CI 1.34--95.82; *P* = 0.026), whereas the TT variant of *TLR7* rs179008 was associated with an 8-fold higher risk of this symptom (OR 8.33, 95% CI 1.06--65.30; *P* = 0.044). No significant association between the examined SNPs and other symptoms was detected.

Associations between *TLR3* and *TLR7* SNPs and HCMV load {#sec011}
---------------------------------------------------------

The viremia levels in HCMV-infected infants ranged from 0 to 3.57 × 10^5^ copies/mL (mean 7.54 × 10^3^ ± 4.64 × 10^4^ copies/mL) in the peripheral blood. The HCMV DNA load in urine samples ranged from 0 to 2.21 × 10^8^ copies/mL (mean 6.82 × 10^6^ ± 3.45 × 10^7^ copies/mL). Despite the considerable differences in viral load, we observed a correlation of the *TLR3* and *TLR7* SNPs with the HCMV DNA concentration in the bodily fluids. The children with heterozygous genotype of rs3775291 had approximately 10-fold increased risk of HCMV disease in an adjusted model that included the HCMV DNA copy number in the whole blood (OR 11.50, 95% CI 3.08--42.97, *P* \< 0.001 in codominant model; [Table 4](#pone.0169420.t004){ref-type="table"}). Similarly, an at least 5-fold increased risk of HCMV infection was observed in these children in an adjusted model that included the HCMV DNA load in urine samples (OR 7.03, 95% CI 1.79--27.62, *P* = 0.008 in codominant model; data not presented). This association reached statistical significance after Bonferroni's correction in almost all genetic models (*P*^*c*^ \< 0.01). The higher viremia levels were also detected in carriers of the heterozygous genotype of the *TLR7* SNP rs5741880 (*P* = 0.007; Mann-Whitney test). However, further studies using larger patient groups are needed to confirm the obtained results. No other associations were observed between the HCMV DNAemia and the examined *TLR* SNPs (*P* \> 0.05).

Haplotype analysis {#sec012}
------------------

Multiple-SNP analysis showed that the most common haplotype for the *TLR3* SNPs rs3775290, rs3775291, rs3775296 and the *TLR7* SNPs rs179008 and rs5741880 was CCCAT (21.5% for uninfected cases) and CTCAG (20.6% for children with HCMV infection). The CTCAG haplotype was associated with increased the risk of HCMV infection in an unadjusted model (OR 51.28, 95% CI 8.71--301.89), and this association reached statistical significance after Bonferroni's correction (*P*^*c*^ \< 0.001). The CTC and TTA haplotype of *TLR3* gene were associated with at least 20-fold increased the risk of HCMV infection in children (*P* = 0.0001 and *P* = 0.0071, respectively, see [Table 6](#pone.0169420.t006){ref-type="table"}). The CTC haplotype association reached statistical significance after Bonferroni's correction (*P*^*c*^ ≤ 0.0063). Performance of haplotype-trait association tests indicated that the TCAT haplotype of *TLR9* gene (rs5743836, rs187084, rs352139, rs352140) was also associated with HCMV infection, although this association did not reach statistical significance after Bonferroni's correction (OR 4.23, 95% CI 1.30--13.70, *P* = 0.018; *P*^*c*^ = 0.005 significance level after Bonferroni's correction). *TLR2* and *TLR7* haplotypes were not associated with the risk of infection.

10.1371/journal.pone.0169420.t006

###### Haplotype analysis of *TLR3* SNPs in children with and without HCMV infection.

![](pone.0169420.t006){#pone.0169420.t006g}

  Haplotype   Frequency (%)   OR (95% CI)   *P*^*c*^                                  
  ----------- --------------- ------------- ---------- ------- ---------------------- ------------
  C           C               C             16.61      50.95   1.00                   NA
  T           C               C             13.47      21.32   1.94 (0.65--5.76)      0.24
  C           T               C             37.37      4.73    26.31 (5.30--130.68)   **0.0001**
  C           T               A             4.28       10.86   1.61 (0.17--15.69)     0.68
  T           T               A             1.22       4.36    20.91 (2.37--184.59)   0.0071
  T           T               C             7.13       5.69    2.78 (0.57--13.52)     0.21
  C           C               A             7.85       1.41    11.86 (0.91--154.56)   0.061
  T           C               A             12.07      0.68    2.42 (0.10--57.63)     0.58

OR: odds ratio; 95% CI: 95% confidence interval; *P*, logistic regression model; NA: not available; *P*^*c*^, The significance level after Bonferroni's correction for multiple testing is 0.0063 (raw *P*-value/8).

We found an association between the SNPs rs3775291 and rs3775296 of *TLR3* (*P* \< 0.001) and *TLR7* SNPs rs179008 and rs5741880 (*P* \< 0.001). In addition, the rs187084 was associated with rs352139 of *TLR9* gene (*P* = 0.002), that confirms previously described finding \[[@pone.0169420.ref024]\]. Linkage disequilibrium analysis revealed that the *TLR3* SNPs rs3775291 and rs3775296 exhibited a moderate level of disequilibrium (correlation coefficient r^2^ = 0.514, standardized disequilibrium coefficient D' = 75). In contrast, all the other regions of genes were not in LD with each other (r^2^ \< 0.2).

Discussion {#sec013}
==========

To our knowledge, no studies have been reported thus far exploring the possible involvement of *TLR3* and *TLR7* polymorphisms in the risk of HCMV infection in children. We selected the L412F SNP of the *TLR3* gene, which seems to be associated with HCMV infection and might have a direct functional correlation with virus replication. This *TLR3* gene variant appeared to be relatively common in HCMV-infected compared to uninfected pediatric patients. Moreover, the presence of the missense C\>T mutation among subjects who were either heterozygous (CT) or homozygous for the minor allele (TT) was associated with a significant increase in symptomatic HCMV infection and viremia load. Hence, we suppose that the L412F variant of the *TLR3* gene may be one of the risk factor for HCMV disease in children.

Different studies strongly suggest that variations in genes encoding *TLRs* influence innate immune response to pathogens and disease outcome. In recent years, we have examined the relationship between single nucleotide polymorphisms in *TLRs* genes and HCMV infection in pediatric patients. At first, genetic polymorphisms in extracellular TLR2, that recognize the HCMV envelope gB and gH, and TLR4 were studied. The results showed that *TLR2* SNPs rs121917874, rs5743708, and *TLR4* SNP rs4986790 are not related to risk of HCMV infection in infants \[[@pone.0169420.ref028]\]. If endosomal TLR9 recognizes CpG oligonucleotides in the intracellular space, we decided to explore the correlation between *TLR9* polymorphisms and HCMV infection. We found that -1486T/C and 2848C/T SNPs were prevalent in HCMV-infected children and were associated with increased the risk of cytomegaly \[[@pone.0169420.ref024]\]. Encouraged by the results concerning the role of Toll-like receptors 3 and 7 in other herpesvirus infections \[[@pone.0169420.ref035]--[@pone.0169420.ref038]\], we recently decided to investigate whether common polymorphisms in these genes are associated with HCMV infection. The use of genotyping results for all *TLRs* SNPs in the current multiple analyses revealed that genetic variability in both *TLR3* and *TLR9* genes may have consequences that can contribute to HCMV disease.

The ability of TLR3 to sense dsRNA and stimulate the production of type I IFNs and inflammatory cytokines suggests that this receptor plays an important role in antiviral defense. This receptor is localized mainly on intracellular vesicles with some cell surface expression. After binding the dsRNA motif on pathogens, TLR3 dimerizes and recruits the TIR domain-containing adaptor protein-inducing IFNβ (TRIF) to the endosome. TRIF recruitment results in signaling to activate the transcription factors IFN regulatory factor 3 (IRF3) and nuclear factor-κB (NF-ĸB), which induce type I IFN expression \[[@pone.0169420.ref008], [@pone.0169420.ref039]\]. Moreover, stimulation of TLR3 with poly(I:C) induced expression of IFN-β and IFN-inducible genes, including pro-inflammatory cytokines and chemokines \[[@pone.0169420.ref039]\]. The relationship between TLR3 and viral infection is highly complex and virus-specific. The role of TLR3 in HCMV infection is still unclear, while its function in mediating immunity against MCMV infection was demonstrated \[[@pone.0169420.ref040]\]. As TLR3-deficient mice display inadequate responses to MCMV infection, it is suggested that TLR3 plays an important role in cytomegalovirus recognition \[[@pone.0169420.ref040]\]. Mice with a mutation in TRIF were found to be more susceptible to MCMV infection \[[@pone.0169420.ref041]\]. In contrast, no role for TLR3 signaling could be demonstrated during experiments in which TLR3 was silenced by siRNA before infection with a wild-type isolate of HCMV. The early HCMV-triggered immune response of human monocyte-derived dendritic cells appears to be independent of the TLR3 pathway \[[@pone.0169420.ref042]\]. In addition, Edelmann et al. \[[@pone.0169420.ref043]\] demonstrated that TLR3 is not required for the generation of effective antiviral responses because the absence of TLR3 does not either alter viral pathogenesis or impair the host\'s generation of adaptive antiviral responses to different viruses, including MCMV.

Increasing evidence suggests that the mutation that leads to the replacement of the leucine (L) residue in amino acid position 412 by a phenylalanine (F) residue (L412F) in the *TLR3* ectodomain plays an important role in viral infection. Our data revealed that the L412F minor allele frequency was 50% in the young children with HCMV infection in comparison to 25.6% in the uninfected Polish children. This is significantly higher than the allele frequency of the European (32%) and the overall populations (23%) ([Table 2](#pone.0169420.t002){ref-type="table"}). The heterozygous or homozygous recessive genotypes of this SNP were consistently associated with a higher risk of HCMV infection and disease development. An additional multiple-SNP analysis, including eleven *TLR2*, *TLR3*, *TLR7*, and *TLR9* polymorphisms, confirmed the essential role of the *TLR3* SNP rs3775291 in cytomegaly. Moreover, these genotypes were detected in patients with a high viremia level. We suggest that the L412F mutation within the *TLR3* gene results in a signaling impairment and could be associated with HCMV infection. In experiments *in vitro*, two amino acid changes (L412F and N284I) in the exon-coding region were demonstrated to impair TLR3 signaling in response to its ligand \[[@pone.0169420.ref044]\]. It was previously shown that genetic variation in *TLR3* affects the host's susceptibility to other herpesvirus infections \[[@pone.0169420.ref035], [@pone.0169420.ref045]\]. The common L412F and the rare non-synonymous substitution rs121434431 (P554S) SNPs were associated with HSV-1 encephalitis \[[@pone.0169420.ref036]\]. The 412F allele carriers were also associated with HSV-2 meningitis \[[@pone.0169420.ref037]\] and recurrent herpes labialis \[[@pone.0169420.ref038]\]. The SNPs at rs3775291 and rs13126816 in the *TLR3* gene were correlated with a reduced incidence of genital HSV-2 infection but did not affect disease severity in the infected hosts \[[@pone.0169420.ref035]\]. The L412F SNP was not associated with HCMV infection in renal transplant recipients, although it was linked with the incidence of acute rejection and graft function \[[@pone.0169420.ref021]\]. This polymorphism was also over-represented in other diseases, including liver recipients infected with human hepatitis C virus \[[@pone.0169420.ref046]\], infants with bronchiolitis \[[@pone.0169420.ref047]\], and individuals with asthma \[[@pone.0169420.ref040]\] or Japanese encephalitis \[[@pone.0169420.ref048]\]. The L412F SNP was also linked with resistance against HIV infection in the Italian population \[[@pone.0169420.ref049]\]. Lower HIV-1 replication and more vigorous immunological responses to TLR3 stimulation were observed in cells from individuals with an L412F mutation in at least one allele when compared with cells from dominant homozygotes.

The structure of the human TLR3 ectodomain revealed a horseshoe shape, characteristic of proteins containing multiple leucine-rich repeats \[[@pone.0169420.ref050]\]. The conserved L412 residue exists within the TLR3 ectodomain, and L412F mutation is very likely to be disruptive to the structure and function of TLR3 \[[@pone.0169420.ref040]\]. It may alter the hydrophobic interactions and affect the glycosylation of neighboring residues that are critical for receptor function and proper TLR3 signaling \[[@pone.0169420.ref026], [@pone.0169420.ref040]\]. Because the rs3775291 SNP is not in the promoter region, it should not influence the mRNA and protein expression of TLR3. However, it was found that this SNP reduces the cell-surface, but not intracellular, TLR3 expression \[[@pone.0169420.ref040]\]. Moreover, the binding capacity of the L412F mutant protein for dsRNA was reduced to half of the wild-type level \[[@pone.0169420.ref051]\]. As the N413A mutation significantly reduces TLR3 signaling \[[@pone.0169420.ref052]\], it is possible that L412F could either affect the glycosylation of asparagine 413 or hinder the interaction of its glycan moiety with dsRNA \[[@pone.0169420.ref053]\]. This may explain the reduced signaling activity of *TLR3* -412F. Nahum et al. \[[@pone.0169420.ref026]\] have found that patient's cells carrying the L412F variant have reduced IFNγ and TNFα in response to stimulation with cytomegalovirus than did cells with the wild-type genotype. This may explain the clinical manifestations exhibited by patients carrying this receptor, such as recurrent viral infections and severe manifestations related to HCMV infection.

We did not find an association between *TLR7* SNP genotypes and the risk of HCMV infection, although higher viremia levels were detected in carriers of the heterozygous genotype of the *TLR7* intronic SNP rs5741880. The polymorphisms in exon 3 of the X-linked *TLR7* gene have been suggested to play a role in the immune response to HCMV glycoproteins. Surprisingly, it was found that SNP rs179008, associated with an amino acid change from glutamine to leucine in position 11 (G11L), was related with variability in HCMV gB antibodies \[[@pone.0169420.ref027]\]. Women with the homozygous variant of this SNP demonstrated a higher vaccination-induced antibody response to gB than did heterozygotes or homozygotes for this allele. Thus far, a functional effect of this SNP was confirmed in other viral diseases, e.g., chronic HCV infection \[[@pone.0169420.ref054]\]. The findings of experiments *in vitro* with plasmacytoid dendritic cells (PDCs) suggest that HCMV induces IFNα secretion from these cells through the engagement of the TLR7 and/or TLR9 pathways \[[@pone.0169420.ref055]\]. Moreover, Epstein-Barr virus interacts with the TLR7 pathway and enhances B cell proliferation \[[@pone.0169420.ref056]\]. Although TLR7 alone does not appear to have a strong role in cytomegalovirus recognition, TLR7/TLR9 and TLR3/TLR7/TLR9 combined deficiencies were shown to impair responses to MCMV \[[@pone.0169420.ref057], [@pone.0169420.ref058]\].

This study has a number of strengths and limitations. The main strength of the present study is the clinical evaluation of children with HCMV infection and the genetic homogeneity of the study population. We selected potentially functional SNPs for our study to increase our chances of identifying polymorphisms related to HCMV disease. However, no population frequencies data were available for these SNPs, so we used HCMV-seronegative newborn infants from our previous cohort study. The genetic variability of our cohort and the European population is very similar. Since HCMV infection was diagnosed in the children after the three weeks of age, it is possible that the patients represent two different populations: congenital and postnatal HCMV infection. Although the number of cases remains small for genetic studies we believe that we have found *TLR* polymorphisms associated with primary HCMV infection. Significant differences in genotype distribution in case-control association study indicate that these polymorphisms remain an important risk factor. Further studies including large numbers of patients are necessary to confirm our findings. Functional analyses may contribute to the understanding of the role of the studied genes in HCMV infection.

In conclusion, the results demonstrate that the L412F polymorphism in the *TLR3* gene is associated with HCMV disease in children. We suggest that this polymorphism conferred reduced secretion of cytokines with antiviral activity, such as IFN and TNFα secretion, and consequently, it could be a genetic risk factor for the development of cytomegaly. Because the L412F SNP is encoded in the exon region, we consider it important to extend this study in the future by performing expression and functional analysis of the TLR3 protein with this SNP. Better understanding of how the host recognizes HCMV and mediates cellular signaling and immune responses is crucial for improving prophylaxis and therapeutic approaches against this important viral pathogen.
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